search
Back to results

Treatment of Behavioral Symptoms in Alzheimer's Disease

Primary Purpose

Alzheimer's Disease, Psychosis, Agitation

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Haloperidol-Haloperidol
Haloperidol-Placebo
Sponsored by
New York State Psychiatric Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer's Disease focused on measuring Alzheimer's disease, psychosis, agitation, haloperidol

Eligibility Criteria

50 Years - 95 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Meets DSM-IV criteria for dementia either sex, age 50-95 years Meets NINCDS-ADRDA criteria for probable Alzheimer's disease Meets Folstein Mini-Mental State Exam score of 5-26, inclusive Intellectual impairment reported for at least six months Availability of family member who has had direct contact with the patient for an average of at least once every week during the three months prior to study entry Has current symptoms of psychosis or agitation. Criteria for "psychosis" requires the presence of delusions and/or hallucinations identified by the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD) and a minimum Brief Psychiatric Rating Scale (BPRS) psychosis factor score of at least 4 (moderate severity) on one of the following two items: These two items comprise the psychosis factor, excluding the item for conceptual disorganization. Agitation is defined as a score of greater than 3 (present at least 10 days per month) on one or more of the CERAD Behavioral Rating Scale for Dementia items for agitation, purposeless wandering, verbal aggression or physical aggression. Free of psychotropic medication for at least two weeks prior to study entry, or able to tolerate medication washout for this period. Informed consent by patient and family member, as per IRB procedures at New York State Psychiatric Institute. Exclusion Criteria: Acute unstable medical condition, delirium, alcohol or substance abuse or dependence within the past 1 year Clinical evidence of stroke, other dementias including vascular or Lewy body or frontotemporal dementia, multiple sclerosis, Parkinson's disease, Huntington's disease, tardive dyskinesia Diagnosis of a psychotic disorder antedating the onset of dementia Antipsychotic medication usage during 4 weeks prior to study entry Contraindication to the use of haloperidol

Sites / Locations

  • New York State Psychiatric Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Haloperidol-Haloperidol

Haloperidol-Placebo

Arm Description

Haloperidol for 20 weeks followed by haloperidol for 24 weeks

Haloperidol for 20 weeks followed by placebo for 24 weeks

Outcomes

Primary Outcome Measures

For the primary hypothesis, the primary endpoint is time to relapse.

Secondary Outcome Measures

Severity of target symptoms at the end of Phase A as a predictor of relapse
Severity of Brief Psychiatric Rating Scale psychosis and hostile suspiciousness factor scores
MMSE and Blessed Functional Activity Scale

Full Information

First Posted
January 23, 2001
Last Updated
May 23, 2016
Sponsor
New York State Psychiatric Institute
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00009217
Brief Title
Treatment of Behavioral Symptoms in Alzheimer's Disease
Official Title
Treatment of Behavioral Symptoms in Alzheimer's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
January 1999 (undefined)
Primary Completion Date
December 2004 (Actual)
Study Completion Date
December 2004 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
New York State Psychiatric Institute
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The optimal strategy for the treatment of behavioral complications in patients with probable Alzheimer's disease (AD) remains unclear. The objective of this study is to evaluate the risk of relapse following discontinuation of haloperidol in patients with Alzheimer's disease (AD) with psychosis or agitation who respond to it. In Phase A of this study, AD outpatients with behavioral complications receive 20 weeks of open haloperidol treatment with an oral dose of 1-5 mg daily, titrated individually to achieve the optimal trade-off between efficacy and side effects. Responders to Phase A participate in Phase B, a 24-week continuation trial in which patients are randomized to continuation haloperidol or placebo. The primary outcome is the time to relapse of psychosis or behavioral disturbance.
Detailed Description
The study involves two phases. Outpatients with AD who meet inclusion/ exclusion criteria enter Phase A, the 20 week open acute treatment phase that uses a flexible dose regimen of haloperidol 1-5 mg daily. Haloperidol is started at an oral dose of 1 mg daily, with subsequent dose titration in 1 mg increments until the optimal dose is reached, i.e., optimal trade-off between efficacy and side effects. At the end of Phase A, patients who do not meet criteria for clinical response exit the protocol and is treated openly with alternative medications. Phase A responders enter Phase B, a 24-week random assignment, placebo-controlled, continuation trial. Randomization is stratified by the severity of dementia and by the presence of psychosis. Half the patients are randomized to haloperidol (continuing at the same dose as at the end of Phase A), and the other half are randomized to placebo. Patients who relapse during Phase B exit the protocol and receive open treatment. In Phase A, patients are followed at 0, 2, 4 weeks and every 4 weeks thereafter until 20 weeks. In the discontinuation trial, Phase B, patients are followed at 0, 1, 2, 4, week time points and every 4 weeks thereafter until 24 weeks. If a patient shows signs of relapse, the patient is brought in for more frequent visits, regardless of the stage of the protocol.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer's Disease, Psychosis, Agitation
Keywords
Alzheimer's disease, psychosis, agitation, haloperidol

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
44 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Haloperidol-Haloperidol
Arm Type
Active Comparator
Arm Description
Haloperidol for 20 weeks followed by haloperidol for 24 weeks
Arm Title
Haloperidol-Placebo
Arm Type
Placebo Comparator
Arm Description
Haloperidol for 20 weeks followed by placebo for 24 weeks
Intervention Type
Drug
Intervention Name(s)
Haloperidol-Haloperidol
Other Intervention Name(s)
Haldol
Intervention Description
Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
Intervention Type
Drug
Intervention Name(s)
Haloperidol-Placebo
Other Intervention Name(s)
Haldol
Intervention Description
Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
Primary Outcome Measure Information:
Title
For the primary hypothesis, the primary endpoint is time to relapse.
Time Frame
0-24 weeks in Phase B
Secondary Outcome Measure Information:
Title
Severity of target symptoms at the end of Phase A as a predictor of relapse
Time Frame
0-24 weeks in Phase B
Title
Severity of Brief Psychiatric Rating Scale psychosis and hostile suspiciousness factor scores
Time Frame
0-20 weeks in Phase A and 0-24 weeks in Phase B
Title
MMSE and Blessed Functional Activity Scale
Time Frame
0-20 weeks in Phase A and 0-24 weeks in Phase B

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Meets DSM-IV criteria for dementia either sex, age 50-95 years Meets NINCDS-ADRDA criteria for probable Alzheimer's disease Meets Folstein Mini-Mental State Exam score of 5-26, inclusive Intellectual impairment reported for at least six months Availability of family member who has had direct contact with the patient for an average of at least once every week during the three months prior to study entry Has current symptoms of psychosis or agitation. Criteria for "psychosis" requires the presence of delusions and/or hallucinations identified by the Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD) and a minimum Brief Psychiatric Rating Scale (BPRS) psychosis factor score of at least 4 (moderate severity) on one of the following two items: These two items comprise the psychosis factor, excluding the item for conceptual disorganization. Agitation is defined as a score of greater than 3 (present at least 10 days per month) on one or more of the CERAD Behavioral Rating Scale for Dementia items for agitation, purposeless wandering, verbal aggression or physical aggression. Free of psychotropic medication for at least two weeks prior to study entry, or able to tolerate medication washout for this period. Informed consent by patient and family member, as per IRB procedures at New York State Psychiatric Institute. Exclusion Criteria: Acute unstable medical condition, delirium, alcohol or substance abuse or dependence within the past 1 year Clinical evidence of stroke, other dementias including vascular or Lewy body or frontotemporal dementia, multiple sclerosis, Parkinson's disease, Huntington's disease, tardive dyskinesia Diagnosis of a psychotic disorder antedating the onset of dementia Antipsychotic medication usage during 4 weeks prior to study entry Contraindication to the use of haloperidol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Davangere Devanand, M.D.
Organizational Affiliation
Columbia University College of Physicians and Surgeon
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York State Psychiatric Institute
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
21845596
Citation
Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43. doi: 10.1002/gps.2630. Epub 2010 Dec 28.
Results Reference
result
Links:
URL
http://www.ncbi.nlm.nih.gov/pubmed/21845596
Description
link to Pubmed abstract

Learn more about this trial

Treatment of Behavioral Symptoms in Alzheimer's Disease

We'll reach out to this number within 24 hrs